Results 91 to 100 of about 169,813 (342)

Network pharmacology-based investigation and experimental validation of the mechanism of metformin in the treatment of acute myeloid leukemia

open access: yesEuropean Journal of Medical Research
Metformin, a widely used anti-diabetic agent, has shown significant anti-cancer properties as reported in in various cancers, including acute myeloid leukemia.
Shaoyu Liu   +5 more
doaj   +1 more source

Hematological diseases and the heart.

open access: yesTurkish journal of medical sciences
The heart, as the main part of the circulatory system, is one of the organs frequently affected by hematological diseases. Cardiac problems may develop during the course and treatment of benign and malignant hematological diseases. This review study was conducted based on recent information from the literature and manifestations of cardiac involvement ...
openaire   +2 more sources

Role of Prednisone and 25(OH) Vitamin D on Bone Mineral Density and Osteoporosis in Systemic Lupus Erythematosus

open access: yesArthritis Care &Research, Accepted Article.
Objective We evaluated the role of 25‐hydroxy vitamin D, prednisone and other risk factors for bone mineral density (BMD) loss and osteoporosis in systemic lupus erythematosus (SLE). Methods We calculated the association between 25‐hydroxy vitamin D [25(OH)D] levels and other potential risk factors with BMD measures (spine T‐scores) and osteoporosis ...
Nima Madanchi   +4 more
wiley   +1 more source

Venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients with RUNX1::RUNX1T1: a retrospective propensity score matching study

open access: yesBlood Cancer Journal, 2023
Miao Wang   +12 more
doaj   +1 more source

Biomaterial Strategies for Targeted Intracellular Delivery to Phagocytes

open access: yesAdvanced Functional Materials, EarlyView.
Phagocytes are essential to a functional immune system, and their behavior defines disease outcomes. Engineered particles offer a strategic opportunity to target phagocytes, harnessing inflammatory modulation in disease. By tuning features like size, shape, and surface, these systems can modulate immune responses and improve targeted treatment for a ...
Kaitlyn E. Woodworth   +2 more
wiley   +1 more source

Next‐Generation Bio‐Reducible Lipids Enable Enhanced Vaccine Efficacy in Malaria and Primate Models

open access: yesAdvanced Functional Materials, EarlyView.
Structure–activity relationship (SAR) optimization of bio‐reducible ionizable lipids enables the development of highly effective lipid nanoparticle (LNP) mRNA vaccines. Lead LNPs show superior tolerability and antibody responses in rodents and primates, outperforming approved COVID‐19 vaccine lipids.
Ruben De Coen   +30 more
wiley   +1 more source

Electrosynthesis of Bioactive Chemicals, From Ions to Pharmaceuticals

open access: yesAdvanced Functional Materials, EarlyView.
This review discusses recent advances in electrosynthesis for biomedical and pharmaceutical applications. It covers key electrochemical materials enabling precise delivery of ions and small molecules for cellular modulation and disease treatment, alongside catalytic systems for pharmaceutical synthesis.
Gwangbin Lee   +4 more
wiley   +1 more source

The Evolving Pharmacotherapeutic Landscape for the Treatment of Sickle Cell Disease. [PDF]

open access: yes, 2020
Sickle cell disease (SCD) is an extremely heterogeneous disease that has been associated with global morbidity and early mortality. More effective and inexpensive therapies are needed.
Ballas, Samir K
core   +1 more source

P403: HIGH EXPRESSION OF STAT5 INDICATES POOR PROGNOSIS IN B CELL ACUTE LYMPHOBLASTIC LEUKEMIA

open access: yesHemaSphere, 2023
Xiuli Xu   +6 more
doaj   +1 more source

The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute lymphoblastic leukemia

open access: yesCancer Medicine
Tyrosine kinase inhibitors (TKIs) have revolutionized Philadelphia chromosome‐positive (Ph+) acute lymphoblastic leukemia (ALL) treatment. The combination of blinatumomab and a TKI in the frontline setting has shown the safety and efficacy of the ...
Xiaoxia Wu   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy